SLC5A2 and diabetes mellitus: Type 2 diabetes mellitus was more frequently observed in the SGLT2 inhibitor group (p = 0.01), while a history of nicotine abuse was more common among patients without SGLT2 inhibitor therapy (p = 0.01).